Abstract
Background Gadolinium-enhanced CMR can be a useful adjunct in the diagnosis and assessment of acute myocardial infarction (AMI). However, gadolinium contrast is contraindicated in severe renal impairment. Alternative, non-gadolinium contrast agents for AMI assessment and contrast-enhanced CMR in general would be of substantial clinical importance. Ferumoxytol, an intravenous iron-supplementation drug, was approved in 2009 by the FDA for treatment of iron-deficiency anemia in patients with chronic kidney disease, and is known to have T1 shortening properties. The utility of T1-weighted ferumoxytol-enhanced CMR for detecting AMI has not been previously evaluated.
Highlights
Gadolinium-enhanced CMR can be a useful adjunct in the diagnosis and assessment of acute myocardial infarction (AMI)
All five animals had AMI verified by pathology, and mean infarct size was 12.7% of LV mass
Pattern two (n=2) demonstrated reduced Ferumoxytol uptake compared with normal myocardium
Summary
Detection of acute myocardial infarct with T1-mapping post ferumoxytol contrast administration. Deneen Spatz1*, Igor Klem, Lowie M Van Assche, Enn-Ling Chen, Wolfgang G Rehwald, Han W Kim, Christoph J Jensen, David Wendell, Elizabeth Jenista, Raymond J Kim. From 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. From 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. 31 January - 3 February 2013
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
